Sonnet BioTherapeutics Holdings Inc【SONN】株式ニュース | ADVFN

US Dollar vs Yen

登録して無料でリアルタイムの株価、インタラクティブチャート、ライブオプションフローなどを入手してください。

登録

ホーム
投資
株式
アメリカ
NASDAQ
Sonnet BioTherapeutics Holdings Inc (SONN)
Sonnet BioTherapeutics Holdings Inc (SONN) ニュース

Sonnet BioTherapeutics Holdings Inc (SONN)

2.63

-0.14

(-5.05%)

終値： 11月28日 6:00AM

2.62

-0.01

( -0.38% )

取引時間後: 8:11AM

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

プレミアム

Form S-8 - Securities to be offered to employees in employee benefit plans

Sonnet BioTherapeutics Releases Virtual Investor ‘”What this Means” Segment

Drs. Pankaj Mohan, CEO of Sonnet, and John Cini, CSO of Sonnet, discuss the Company’s recent issuance of a U.S...

Form 8-K - Current report

Form 424B4 - Prospectus [Rule 424(b)(4)]

Form EFFECT - Notice of Effectiveness

Sonnet BioTherapeutics Announces Pricing of $5.0 Million Underwritten Public Offering Priced At-The-Market Under Nasdaq Rules

PRINCETON, NJ, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the "Company" or...

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]

Form 8-K - Current report

Sonnet BioTherapeutics Announces Issuance of U.S. Patent Covering a Variant IL-18 Incorporated into Two Novel Immunotherapeutic Drug Candidates

Both novel bifunctional (SON-1411) and monofunctional (SON-1400) fusion proteins exhibit wild-type binding to...

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]

Form S-1 - General form for registration of securities under the Securities Act of 1933

Form 8-K - Current report

Sonnet BioTherapeutics Inc. Regains Compliance with Nasdaq

PRINCETON, NJ, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the “Company” or...

Form 8-K - Current report

Sonnet BioTherapeutics Inc. Enters into Licensing Agreement with Alkem Laboratories Limited to Develop and Commercialize SON-080 for Diabetic Peripheral Neuropathy (DPN) in India

Sonnet to receive $1.0 million in upfront payment and up to an additional$1.0 million in milestone payments...

tw0122

Reverse split was September

Invest-in-America

Invest-in-America 3週前

SONN: They announced a DUMP-to-Market routine!!! (The WORST thing any firm could do when their stock is SOARING!!!! WOW!!!!)

Tiger Money

Tiger Money 3週前

What is going on here? Reverse? Where is the float on this train wreck now?

bigfart

bigfart 3週前

So insiders can dump before the RS

tw0122

Reverse split offering and now some news $8s

tw0122

May the reverse split gods come soon. Keep an eye!

BooDog

Another split here too.

https://www.globenewswire.com/news-release/2024/09/25/2952951/0/en/Sonnet-BioTherapeutics-Announces-1-for-8-Reverse-Stock-Split.html

Clemdane

Clemdane 3月前

Big jump today!

Awl416

Sonnet BioTherapeutics Enters into Clinical Collaboration Agreement to Commence Investigator-Initiated and Funded Phase 1/2a Study of SON-1210 in Combination with Chemotherapy for the Treatment of Pancreatic Cancer

Monksdream

Monksdream 3月前

SONN new 52=low

Clemdane

Clemdane 3月前

Big jump back up today. It's a very "risk on" stock so when the market is scared, everyone dumps it.

Monksdream

Monksdream 3月前

SONN new 52 week low

Monksdream

Monksdream 4月前

SONN new 52 week low

Monksdream

Monksdream 5月前

SONN new 52 week low

Monksdream

Monksdream 5月前

SONN new 52 week low

BooDog

I see 76 followers here. And I have a target price of around 1.50 for support.

GL.

I do own shares and am looking for this to have a good future.

maq1214

maq1214 8月前

Something must be happening behind closed doors. This stock has been ridiculously quite since the RS. Glad it’s greening again !

81vette

81vette 8月前

23,198 watchers now,word is spreading like wildfire,somebody with lots of followers must be promoting this

81vette

81vette 8月前

They are rare,not 1 in a million lotto rare but only a few per year maybe happen,the chart is great,how many bio pharma are bullish for 5 months straight (1 in a million lol) has accumulated also and that is very promising

maq1214

maq1214 8月前

Do you think we are likely to see a merger/ partnership? I;m really hoping the reverse split last year cost me a lot

81vette

81vette 8月前

$2.23 is 5 month high,next res. $5 mental,$7.57(sma200),big gaps to fill,mental 10/15/20/25 ect. lots of blue sky past 7.57,any kind of merger/buyout news could send it,thats the hype/hope/pump talk right now

81vette

81vette 8月前

254k short,could squeeze with ZERO BORROW,73% fee(no rebate),5 months of accumulation= in the know are loading

81vette

81vette 8月前

5 month uptrend(since r/s)accumulation,zero borrow,moving today on low vol(up13%),clinical trials different stages,float 2.78m,o/s 3m

BooDog

Riding free again.

Monksdream

Monksdream 9月前

crowin

Chardan Capital Maintains Buy on Sonnet BioTherapeutics, Lowers Price Target to $30

maq1214

maq1214 9月前

This should get exciting soon, crazy volume yesterday !

BooDog

BooDog 10月前

IS it just greed or might this make good for another round trip? We'll see next week.

BooDog

BooDog 11月前

Good move IMO. Surprising actually.

On December 27, 2023, the Compensation Committee (the “Committee”) of the Board of Directors of Sonnet BioTherapeutics Holdings, Inc. (the “Company”) cancelled accrued but unpaid bonuses (the “Cancelled Bonuses”) that had been awarded for fiscal years 2022 and 2023 by the Committee to certain executive officers and employees of the Company. The Cancelled Bonuses total $1,930,773.10 and include (i) $631,768.12 awarded to Pankaj Mohan, Ph.D., the Company’s President and Chief Executive Officer, (ii) $312,741.79 awarded to John Cini, Ph.D, the Company’s Chief Scientific Officer and (iii) $364,504.40 awarded to Jay Cross, the Company’s Chief Financial Officer.

https://ih.advfn.com/stock-market/NASDAQ/sonnet-biotherapeutics-SONN/stock-news/92897290/form-8-k-current-report

Monksdream

Monksdream 1年前

SONN new 52 week low

BooDog

Discount. Maybe I should have added "again". 1.60 offering and this is pushing towards the $. Very small float. Just playing the bounce. IF there is one lol.

https://www.accesswire.com/viewarticle.aspx?id=796208

valleybenedetto

valleybenedetto 1年前

Absolute piece of shit co, shit stock, dilution is endless. CEO should be fired. Sell now

Monksdream

Monksdream 1年前

SONN new 52 week low

Monksdream

Monksdream 1年前

SONN new 52 week low

Monksdream

Monksdream 1年前

SONN new 52 week low

Monksdream

Monksdream 1年前

SONN new 52 week low

valleybenedetto

valleybenedetto 1年前

If they would stop shitting on shareholders, cut costs and actually get something accomplished that would be a start.

Monksdream

Monksdream 1年前

If the stock continues to make new lows on its way to a delisting to Cromwell Coulson’s stock market or a dissolution I will continue to record it

valleybenedetto

valleybenedetto 1年前

You worry about you ok?

Monksdream

Monksdream 1年前

You aren’t getting any money back
Time to move on

valleybenedetto

valleybenedetto 1年前

Not an Urban Myth ..I've already checked. They have current D and O insurance.

Monksdream

Monksdream 1年前

Oh goddamn tell me another urban myth

valleybenedetto

valleybenedetto 1年前

They have D and O insurance. That's where you collect from. That's directors and officers insurance if you didn't know

Monksdream

Monksdream 1年前

You wouldn’t get anything from a class action lawsuit
Anyone connected to professional asset management abandoned this company long ago

valleybenedetto

valleybenedetto 1年前

CEO is awful. Nothing but offerings and RS. No meaningful news in months. Class action suit might be in order here.

Monksdream

Monksdream 1年前

SONN new 52 week low

Golden Cross

Golden Cross 1年前

Might be a short play here now

Golden Cross

Golden Cross 1年前

antman

...During his testimony, Elon Musk called short selling “a means for, in my opinion, bad people on Wall Street to steal money from small investors.”

tw0122

Biotech CEOs are mostly Wall Street whores they get compensated to short there own companies as it’s much more lucrative. They take on that toxic financing do reverse splits as part of their regular routine. Take MULN CEO for example he has no scruples or morals nor does he hide his screwing over shareholders.
As far as trading you play the post reverse splits at the right time with the low float and that is where the loot is made.
Wall Street casino.

Sonnet BioTherapeutics

BNP Paribas Issuance

BMO Women in Leadership ...

Lyxor UCITS ETF STOXX Eu...

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約